Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease | Zendy

Álvaro Avezum | Zendy; Renato D. Lópes | Zendy; Phillip J. Schulte | Zendy; Fernando Laņas | Zendy; Bernard J. Gersh | Zendy; Michael Hanna | Zendy; Prem Pais | Zendy; Çetin Erol | Zendy; Rafael Díaz | Zendy; M. Cecilia Bahit | Zendy; Jozef Bartunek | Zendy; Raffaele De Caterina | Zendy; Shinya Goto | Zendy; Witold Rużyłło | Zendy; Jun Zhu | Zendy; Christopher B. Granger | Zendy; John H. Alexander | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Author(s) -

Álvaro Avezum,

Renato D. Lópes,

Phillip J. Schulte,

Fernando Laņas,

Bernard J. Gersh,

Michael Hanna,

Prem Pais,

Çetin Erol,

Rafael Díaz,

M. Cecilia Bahit,

Jozef Bartunek,

Raffaele De Caterina,

Shinya Goto,

Witold Rużyłło,

Jun Zhu,

Christopher B. Granger,

John H. Alexander

Publication year - 2015

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.114.014807

Subject(s) - medicine , apixaban , atrial fibrillation , warfarin , valvular heart disease , cardiology , heart disease , rivaroxaban

Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research